BioWorld Asia

Dec. 17, 2003

Acambis Files 'First-Ever' BLA: Arilvax Vaccine In Yellow Fever

Acambis plc filed a biologics license application seeking approval of Arilvax as a vaccine to prevent yellow fever. (BioWorld International) Read More

Arpida Moving Iclaprim Into Phase III Trial, Seeking EUR25M

Trial To Test Recombinant Poxvirus Vaccine In Malaria

Genmab Stops HuMax-CD4 Development In Psoriasis

Ingenium Plans Growth After Third Round Brings In EUR13.8M

Benitec Settles ddRNAi Dispute, Raises A$10.9M To Fund Growth

Faust Pharmaceuticals Acquires Euroclide, Seeks EUR12M Funding

Innate Pharma, Novo Nordisk In Cancer Immunotherapy Deal

Novacea Licenses Cancer Drug From KuDOS Pharmaceuticals

London Cluster Growing But Lab Space Shortage Impedes

EU Moving Closer To New Rules On Pharmaceuticals, Tissues, Cells

Industry Representatives Meet In Israel To Discuss Bioengineering

Fulcrum To Help Addex Build Internal Clinical Development

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...